How do you determine CHB treatment eligibility when ALT may be driven by metabolic dysfunction–associated steatotic liver disease (e.g., obesity/diabetes)—what data do you prioritize (HBV DNA trends, fibrosis assessment, or other markers) to avoid both undertreatment and misattribution of ALT?